Alcon Laboratories, Inc.

Alcon Research, Ltd.

Robert G Harris

Rajni Jani

Robert E Roehrs

Philip D Gressel

Gregory Bydlinski

Britt S Scott

The present invention is directed to an improved process for producing substantially pure fluorescein, as well as to substantially pure fluorescein compositions prepared by the process. The invention is particularly directed to the provision of pharmaceutical compositions for use in angiography. The substantially pure fluorescein produced by the process of the present invention is low in color, low in sodium chloride content, and substantially free of pyridine.

Substantially pure fluorescein

Disclosed are nonstinging, sustained release ophthalmic formulations to control intraocular pressure in antiglaucoma therapy comprising a basic active, a cation exchange resin, and, inter alia, an acidic, mucomimetic polymer. Also disclosed are methods of treatment comprising administering such formulations topically to the eye when indicated for control and lowering of intraocular pressure.

Sustained release comfort formulation for glaucoma therapy

Disclosed is a liquid ophthalmic composition of unique rheological and lubricating properties comprising, inter alia, a polyanionic polymer for use as a long lasting artificial tear. Also disclosed is a method of treatment comprising topically administering the composition when indicated for relief of dry eye syndrome, foreign body sensation, burning, hyperemia, corneal staining, and the like.

Ophthalmic solution

Sustained release, comfort formulation for glaucoma therapy

Growing community of inventors

Fort Worth, TX, United States of America

Robert G Harris